Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767494 | 0.91 | SCD (0.47) | SCDMMP13ALDH1A1 | |
| SCHEMBL1767391 | 0.87 | SCD (0.52) | SCDALDH1A1ROCK1 | |
| SCHEMBL1767560 | 0.87 | SCD (0.50) | SCDMMP13ALDH1A1ROCK2KLKB1 | |
| SCHEMBL1767389 | 0.86 | SCD (0.50) | SCDMMP13CXCR3HTR7KLKB1 | |
| SCHEMBL1767520 | 0.84 | SCD (0.50) | SCDHTR7ROCK2 | |
| SCHEMBL1767518 | 0.84 | SCD (0.65) | SCDALDH1A1 | |
| SCHEMBL1767498 | 0.83 | SCD (0.51) | SCD | |
| SCHEMBL1767575 | 0.82 | SCD (0.53) | SCDALDH1A1 | |
| SCHEMBL1767542 | 0.81 | SCD (0.49) | SCDALDH1A1 | |
| SCHEMBL1767539 | 0.80 | ROCK2 (0.42) | SCDACHEGSK3BROCK2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | claimed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | claimed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| WO-2009156484-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105530-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885MMP13 1303/4885ALDH1A1 451/4885 |
| US-20160289191-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885MMP13 1303/4885ALDH1A1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.